Chengdu Kanghua Biological Products Co. Td Class 1

Chengdu Kanghua Biological Products Co. Td Class 1

SSZSE:300841
47.02
CNY
+0.07
(+0.15%)
1.92EPS
28.38P/E
7.32BMarket Cap
Apr 19Next Earn

Total Valuation

CNY

As of September 30, 2026, Chengdu Kanghua Biological Products Co. Td Class 1 carries a market capitalization of 7.32B, placing it among publicly traded companies globally. Its enterprise value stands at 6.37B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap7.32B
Enterprise Value6.37B

Important Dates

Chengdu Kanghua Biological Products Co. Td Class 1's next confirmed earnings release is scheduled for April 19, 2027.

Earnings Date4/19/2027

Share Statistics

As of September 30, 2026, Chengdu Kanghua Biological Products Co. Td Class 1 has 129.95M shares outstanding.

Shares Outstanding129.95M

Valuation Ratios

As of September 30, 2026, Chengdu Kanghua Biological Products Co. Td Class 1 trades at a trailing price-to-earnings ratio of 28.38. The price-to-sales ratio is 6.05, and the price-to-book ratio stands at 1.98.

PE Ratio28.38
PS Ratio6.05
PB Ratio1.98
P/TBV Ratio2.18

Enterprise Valuation

As of September 30, 2026, Chengdu Kanghua Biological Products Co. Td Class 1 trades at an EV/EBITDA multiple of 22.20 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.27 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 22.20 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 6.37B versus a market cap of 7.32B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales5.27
EV / EBITDA22.20
EV / EBIT22.20

Financial Position

As of September 30, 2026, Chengdu Kanghua Biological Products Co. Td Class 1 maintains a current ratio of 7.42, meaning it holds 7.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.12, indicating conservative leverage, while an interest coverage ratio of 237.53 demonstrates strong ability to service its debt obligations.

Current Ratio7.42
Quick Ratio3.32
Debt / Equity0.12
Debt / EBITDA0.02
Interest Coverage237.53

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Chengdu Kanghua Biological Products Co. Td Class 1 posted a return on equity (ROE) of 7.24, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.60 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.26, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 6.89, useful for judging operating efficiency across full business cycles. The company generates approximately 2.19M in revenue per employee across its workforce of 553.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.83 indicates how many times Chengdu Kanghua Biological Products Co. Td Class 1 sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)7.24
Return on Assets (ROA)6.26
Return on Invested Capital (ROIC)6.60
Return on Capital Employed (ROCE)6.89
Revenue Per Employee2.19M
Employee Count553.00
Inventory Turnover0.83

Taxes

CNY

Over the twelve months ended September 30, 2026, Chengdu Kanghua Biological Products Co. Td Class 1 recorded 37.69M in income tax expense. That works out to an effective tax rate of 13.15, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 286.63M, leaving 258.05M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax37.69M
Effective Tax Rate13.15

Stock Price Statistics

CNY

As of the close on November 17, 2026, Chengdu Kanghua Biological Products Co. Td Class 1's stock has declined approximately 42.71% over the past 52 weeks. The 50-day moving average sits at 50.82, while the 200-day moving average is 54.36.

52-Week Price Change-42.71%
50-Day Moving Average50.82
200-Day Moving Average54.36

Income Statement

CNY

Over the twelve months ended September 30, 2026, Chengdu Kanghua Biological Products Co. Td Class 1 generated 1.21B in revenue and converted that into 258.05M in net income, yielding earnings per share of 1.92. EBITDA reached 286.96M, while operating income came in at 294.69M.

Revenue1.21B
Gross Profit1.09B
Operating Income294.69M
Pretax Income286.63M
Net Income258.05M
EBITDA286.96M
EBIT286.96M
Earnings Per Share (EPS)1.92

Balance Sheet

CNY

As of September 30, 2026, Chengdu Kanghua Biological Products Co. Td Class 1 holds 1.19B in cash and equivalents against 4.74M in total debt, resulting in a net debt position of -310.36M. Total book value stands at 3.70B, with working capital of 2.30B providing operational flexibility.

Cash & Cash Equivalents1.19B
Total Debt4.74M
Net Debt-310.36M
Equity (Book Value)3.70B
Book Value Per Share28.48
Working Capital2.30B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-52.23M

Margins

Over the twelve months ended September 30, 2026, Chengdu Kanghua Biological Products Co. Td Class 1 posted a gross margin of 89.72, reflecting its pricing power and cost economics. The operating margin of 24.36 and net profit margin of 21.33 provide insight into operational efficiency.

Gross Margin89.72
Operating Margin24.36
Pretax Margin23.70
Profit Margin21.33
EBITDA Margin23.72

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Chengdu Kanghua Biological Products Co. Td Class 1 paid dividends of 0.51 per share. The dividend payout ratio of 26.61 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.96, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Chengdu Kanghua Biological Products Co. Td Class 1 shareholders.

Dividend Per Share0.51
Payout Ratio26.61
Shareholder Yield2.96

Stock Splits

Chengdu Kanghua Biological Products Co. Td Class 1's most recent stock split took place on May 25, 2022 with a 2:3 split ratio.

Last Split Date5/25/2022
Split Ratio2:3

Scores

As of September 30, 2026, Chengdu Kanghua Biological Products Co. Td Class 1 has an Altman Z-Score of 11.44, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score11.44